# Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma

> **NCT04108377** · PHASE1 · TERMINATED · sponsor: **University of California, Davis** · enrollment: 5 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04108377
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-21
- **Primary completion:** 2022-12-11
- **Final completion:** 2023-08-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Enrollment stopped secondary to completion of funding
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108377, "Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04108377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*